Abstract
Background: Both PH are approved for use in patients with HER2-positive breast cancer and are available as intravenous formulations (PH IV) and subcutaneous fixed-dose combination of both drugs (PH FDC SC). SC formulations showed similar efficacy as IV counterparts, providing additional economic value to patients, physicians and health systems due to shorter administration and observation time.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
